Strata Critical Medical (SRTA) Revenue (2020 - 2026)

Strata Critical Medical (SRTA) has 7 years of Revenue data on file, last reported at $67.4 million in Q1 2026.

• Revenue for Q1 2026 came in at $67.4 million, up 87.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $254.3 million (up 44.19% YoY), and the FY2025 annual result was $197.1 million, up 34.28% from the prior year.
• Revenue advanced to $67.4 million in Q1 2026 per SRTA's latest filing, from $66.8 million in the prior quarter.
• Over five years, Revenue peaked at $71.4 million in Q3 2023 and troughed at $26.6 million in Q1 2022.
• A 5-year average of $51.3 million and a median of $49.3 million in 2025 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2024: Revenue soared 187.18% in 2022, then slumped 49.52% in 2024.
• A 5-year view of Revenue shows it stood at $35.6 million in 2022, then surged by 33.24% to $47.5 million in 2023, then slipped by 23.36% to $36.4 million in 2024, then soared by 83.54% to $66.8 million in 2025, then climbed by 0.89% to $67.4 million in 2026.
• Business Quant data shows SRTA's Revenue at $67.4 million in Q1 2026, $66.8 million in Q4 2025, and $49.3 million in Q3 2025.